Bioventus (BVS) Competitors $7.14 +0.29 (+4.29%) As of 07/3/2025 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BVS vs. NVCR, LMAT, EYE, ENOV, CNMD, AORT, CDRE, TNDM, ESTA, and LQDAShould you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Artivion (AORT), Cadre (CDRE), Tandem Diabetes Care (TNDM), Establishment Labs (ESTA), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry. Bioventus vs. Its Competitors NovoCure LeMaitre Vascular National Vision Enovis CONMED Artivion Cadre Tandem Diabetes Care Establishment Labs Liquidia Technologies NovoCure (NASDAQ:NVCR) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment. Which has higher earnings & valuation, NVCR or BVS? Bioventus has lower revenue, but higher earnings than NovoCure. Bioventus is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovoCure$605.22M3.26-$168.63M-$1.51-11.73Bioventus$567.70M1.03-$156.23M-$0.48-14.88 Is NVCR or BVS more profitable? Bioventus has a net margin of -7.11% compared to NovoCure's net margin of -26.41%. Bioventus' return on equity of 15.61% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets NovoCure-26.41% -45.46% -13.34% Bioventus -7.11%15.61%4.01% Do analysts recommend NVCR or BVS? NovoCure currently has a consensus price target of $32.83, indicating a potential upside of 85.45%. Bioventus has a consensus price target of $14.33, indicating a potential upside of 100.63%. Given Bioventus' higher possible upside, analysts plainly believe Bioventus is more favorable than NovoCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Bioventus 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more volatility & risk, NVCR or BVS? NovoCure has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Does the media prefer NVCR or BVS? In the previous week, NovoCure had 8 more articles in the media than Bioventus. MarketBeat recorded 8 mentions for NovoCure and 0 mentions for Bioventus. Bioventus' average media sentiment score of 1.11 beat NovoCure's score of 0.39 indicating that Bioventus is being referred to more favorably in the news media. Company Overall Sentiment NovoCure Neutral Bioventus Positive Do institutionals & insiders have more ownership in NVCR or BVS? 84.6% of NovoCure shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 5.5% of NovoCure shares are owned by company insiders. Comparatively, 33.0% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryBioventus beats NovoCure on 10 of the 15 factors compared between the two stocks. Get Bioventus News Delivered to You Automatically Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BVS vs. The Competition Export to ExcelMetricBioventusSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$586.84M$256.81M$5.50B$20.64BDividend YieldN/AN/A5.38%3.74%P/E Ratio-11.715.9227.5028.09Price / Sales1.0373.83389.6454.25Price / Cash12.58196.1236.6322.31Price / Book2.556.128.074.59Net Income-$156.23M-$27.18M$3.17B$986.06M7 Day Performance5.52%-1.14%2.81%2.78%1 Month Performance9.40%-7.16%3.69%5.41%1 Year Performance21.29%25.77%35.40%14.61% Bioventus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BVSBioventus3.4318 of 5 stars$7.14+4.3%$14.33+100.6%+21.3%$586.84M$567.70M-11.711,200Positive NewsNVCRNovoCure3.7133 of 5 stars$17.80-1.1%$32.83+84.5%+4.9%$2.01B$605.22M0.001,488LMATLeMaitre Vascular2.6079 of 5 stars$83.05+0.6%$97.83+17.8%+3.8%$1.87B$219.86M41.70490Positive NewsEYENational Vision2.6844 of 5 stars$23.01-0.7%$18.67-18.9%+92.2%$1.83B$1.82B64.3613,411ENOVEnovis3.5582 of 5 stars$31.36-1.3%$58.00+84.9%-24.2%$1.82B$2.11B10.127,367Positive NewsCNMDCONMED4.725 of 5 stars$52.10-0.1%$62.20+19.4%-19.5%$1.61B$1.31B12.083,900AORTArtivion2.5506 of 5 stars$31.17-0.1%$32.00+2.7%+18.8%$1.33B$388.54M124.761,600CDRECadre3.6998 of 5 stars$31.94-0.3%$37.50+17.4%-5.3%$1.30B$567.56M33.722,284TNDMTandem Diabetes Care4.3076 of 5 stars$18.64-1.6%$33.43+79.3%-57.1%$1.26B$940.20M0.002,650Positive NewsESTAEstablishment Labs1.4078 of 5 stars$42.71+4.3%$52.40+22.7%+0.4%$1.18B$166.02M0.001,018LQDALiquidia Technologies3.2699 of 5 stars$12.46-4.9%$26.89+115.8%+2.4%$1.12B$14M0.0050Positive News Related Companies and Tools Related Companies NovoCure Alternatives LeMaitre Vascular Alternatives National Vision Alternatives Enovis Alternatives CONMED Alternatives Artivion Alternatives Cadre Alternatives Tandem Diabetes Care Alternatives Establishment Labs Alternatives Liquidia Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BVS) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BVS Stock Alerts